REGN - Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry | Benzinga
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Regeneron Pharmaceuticals (NASDAQ:REGN) and its primary competitors in the Biotechnology industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
Regeneron Pharmaceuticals Background
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | |||||||
| 29.21 | |||||||
| 4.04 | |||||||
| 8.61 | |||||||
| 2.73% | |||||||
| $0.83 | |||||||
| $2.71 | |||||||
| -0.54% | |||||||
| AbbVie Inc | |||||||
| 47.68 | |||||||
| 35.33 | |||||||
| 5.22 | |||||||
| 14.8% | |||||||
| $4.49 | |||||||
| $8.22 | |||||||
| 0.7% | |||||||
| Amgen Inc | |||||||
| 43.92 | |||||||
| 32.84 | |||||||
| 5.60 | |||||||
| -2.01% | |||||||
| $2.15 | |||||||
| $4.25 | |||||||
| 21.98% | |||||||
| Vertex Pharmaceuticals Inc | |||||||
| 30.53 | |||||||
| 6.55 | |||||||
| 12.04 | |||||||
| 6.09% | |||||||
| $1.34 | |||||||
| $2.35 | |||||||
| 13.3% | |||||||
| Gilead Sciences Inc | |||||||
| 176.19 | |||||||
| 4.51 | |||||||
| 2.90 | |||||||
| -20.66% | |||||||
| $-3.54 | |||||||
| $5.13 | |||||||
| 5.26% | |||||||
| Biogen Inc | |||||||
| 28.73 | |||||||
| 2.20 | |||||||
| 3.47 | |||||||
| 2.62% | |||||||
| $0.68 | |||||||
| $1.75 | |||||||
| -7.0% | |||||||
| BioNTech SE | |||||||
| 201.74 | |||||||
| 1.14 | |||||||
| 8.39 | |||||||
| -1.57% | |||||||
| $-0.29 | |||||||
| $0.13 | |||||||
| -85.31% | |||||||
| Genmab A/S | |||||||
| 23.93 | |||||||
| 3.94 | |||||||
| 7.36 | |||||||
| 4.13% | |||||||
| $1.72 | |||||||
| $3.96 | |||||||
| 46.19% | |||||||
| Biomarin Pharmaceutical Inc | |||||||
| 72.09 | |||||||
| 2.86 | |||||||
| 5.96 | |||||||
| 1.77% | |||||||
| $0.14 | |||||||
| $0.52 | |||||||
| 8.79% | |||||||
| Neurocrine Biosciences Inc | |||||||
| 38.02 | |||||||
| 5.90 | |||||||
| 7.24 | |||||||
| 1.88% | |||||||
| $0.04 | |||||||
| $0.51 | |||||||
| 22.57% | |||||||
| Incyte Corp | |||||||
| 17.82 | |||||||
| 2.45 | |||||||
| 3.53 | |||||||
| 3.2% | |||||||
| $0.26 | |||||||
| $0.82 | |||||||
| 8.93% | |||||||
| United Therapeutics Corp | |||||||
| 13.07 | |||||||
| 2.29 | |||||||
| 5.49 | |||||||
| 5.42% | |||||||
| $0.43 | |||||||
| $0.6 | |||||||
| 33.7% | |||||||
| Sarepta Therapeutics Inc | |||||||
| 288.91 | |||||||
| 12.22 | |||||||
| 8.42 | |||||||
| 3.97% | |||||||
| $0.05 | |||||||
| $0.36 | |||||||
| 63.1% | |||||||
| Roivant Sciences Ltd | |||||||
| 2.08 | |||||||
| 1.35 | |||||||
| 72.45 | |||||||
| -2.51% | |||||||
| $-0.18 | |||||||
| $0.02 | |||||||
| 5.68% | |||||||
| Average | |||||||
| 75.75 | |||||||
| 8.74 | |||||||
| 11.39 | |||||||
| 1.32% | |||||||
| $0.56 | |||||||
| $2.2 | |||||||
| 10.61% |